CRP may track TB treatment in Kenyan children, not diagnose it

Tuberculosis (TB) in children presents diagnostic and management challenges, and researchers led by Joy Githua investigated whether a blood marker called C-reactive protein (CRP) could help. In this work, CRP was studied for two related purposes: as a diagnostic screening test to separate children with TB from those without, and as a way to monitor how children respond to TB treatment over time. The study population was described as Kenyan children, and the analysis separated cases into confirmed TB and unconfirmed TB where relevant. The team compared CRP levels at the time of diagnosis between children who ultimately had TB and those who did not, and they measured how CRP levels changed during the course of treatment in children diagnosed with TB. The aim was to see whether CRP could serve either as a reliable, simple screening tool at the point of diagnosis or as an objective marker that falls as treatment succeeds. The work focused strictly on CRP measurements and on how those measurements related to diagnostic status and to changes during therapy among the children studied.

The report summarizes key findings about CRP’s diagnostic and monitoring performance. For diagnostic screening, the researchers found that CRP levels did not differ significantly between children with TB and those without TB, indicating CRP alone was not able to distinguish the two groups at diagnosis. In contrast, when the team looked at CRP over the course of TB treatment they observed significant declines in median CRP levels. The abstract states that median CRP levels decreased significantly during TB treatment in confirmed TB cases (p=0.03) and in unconfirmed TB cases (p=0.002), suggesting a treatment-related fall. The summary portion of the abstract reiterates the decrease during treatment and reports slightly different p-values: confirmed (p=0.02) and unconfirmed TB (p<0.001). While the abstract does not provide further methodological detail in this summary, it presents a clear result: CRP did not separate cases at diagnosis but did fall with treatment in both confirmed and unconfirmed pediatric TB.

Taken together, these results lead to a cautious, practical conclusion. According to the abstract, CRP’s diagnostic screening performance was suboptimal and therefore CRP should not be relied on as a stand-alone test to diagnose TB in children. At the same time, the consistent decreases in median CRP during the course of treatment — reported for both confirmed and unconfirmed TB — point to a potential role for CRP as a marker of treatment response in pediatric TB. In plain terms, CRP may be of value to clinicians or programs as a way to check whether a child’s inflammatory marker is falling during therapy, even if it cannot be used to decide who has TB at the outset. The study’s summary emphasizes this distinction: while CRP does not perform well as a screening diagnostic, the observed declines during treatment suggest utility for monitoring response in children with TB.